Investigation of clearance of amyloid beta from the brain by IVIg

Investigation of clearance of amyloid beta from the brain by IVIg - Investigation of clearance of Abeta from the brain by IVIg

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022319

Enrollment

Registered

2016-09-08

Start date

2012-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer disease

Interventions

Intravenous immunogloblin therapy 0.4g/kg/day x 3 days 3 cycles

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with mild cognitive impairment due to AD (Minimental state examination <28) or Patients with probable AD

Exclusion criteria

Exclusion criteria: Women of childbearing potential Presence of pacemakers, or foreign metal objects in the body Prior treatment experimental immunotherapeutics or vaccines for AD

Design outcomes

Primary

Measure	Time frame
levels of amyloid beta in plasma from juglar vein and from peripheral vein. levels of amyloid beta in cerebrospinal fluid Mini Mental State Examination	—

Countries

Japan

Contacts

Public ContactTakashi Kasai

Kyoto Prefectural University of Medicine Neurology

kasaita@koto.kpu-m.ac.jp0752515794

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026